Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-04-09 09:00 am Unchanged | 2025-04-09 | 13D | ESSA Pharma Inc. EPIX | BIOTECHNOLOGY VALUE FUND LP | 8,748,629 19.700% | 0 (Unchanged) | Filing History |
| 2025-02-14 4:28 pm Purchase | 2024-12-31 | 13G | VistaGen Therapeutics, Inc. VTGN | BIOTECHNOLOGY VALUE FUND LP | 3,084,324 9.970% | 307,079 (+11.06%) | Filing History |
| 2025-02-14 4:26 pm Purchase | 2024-12-31 | 13G | Verastem, Inc. VSTM | BIOTECHNOLOGY VALUE FUND LP | 4,706,551 9.990% | 427,030 (+9.98%) | Filing History |
| 2025-02-14 4:24 pm Sale | 2024-12-31 | 13G | Tyra Biosciences, Inc. TYRA | BIOTECHNOLOGY VALUE FUND LP | 3,944,194 7.800% | -717,000 (-15.38%) | Filing History |
| 2025-02-14 4:22 pm Sale | 2024-12-31 | 13G | Ikena Oncology, Inc. IKNA | BIOTECHNOLOGY VALUE FUND LP | 4,006,564 8.300% | -762,600 (-15.99%) | Filing History |
| 2025-02-14 4:20 pm Sale | 2024-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | BIOTECHNOLOGY VALUE FUND LP | 4,834,297 9.990% | -2,548,345 (-34.52%) | Filing History |
| 2025-02-14 4:11 pm Purchase | 2024-12-31 | 13G | Forte Biosciences, Inc. FBRX | BIOTECHNOLOGY VALUE FUND LP | 643,622 9.990% | 643,622 (New Position) | Filing History |
| 2025-02-14 4:07 pm Sale | 2024-12-31 | 13G | 89bio, Inc. ETNB | BIOTECHNOLOGY VALUE FUND LP | 4,333,885 3.600% | -2,477,746 (-36.38%) | Filing History |
| 2025-02-14 4:05 pm Purchase | 2024-12-31 | 13G | Cidara Therapeutics, Inc. CDTX | BIOTECHNOLOGY VALUE FUND LP | 1,093,499 9.990% | 390,373 (+55.52%) | Filing History |
| 2025-02-14 4:02 pm Purchase | 2024-12-31 | 13G | Avalo Therapeutics, Inc. AVTX | BIOTECHNOLOGY VALUE FUND LP | 1,038,542 9.990% | 71,243 (+7.37%) | Filing History |
| 2025-02-04 8:09 pm Purchase | 2025-01-27 | 13G | Kura Oncology, Inc. KURA | BIOTECHNOLOGY VALUE FUND LP | 5,912,554 7.500% | 2,504,500 (+73.49%) | Filing History |
| 2025-02-04 8:05 pm Sale | 2024-12-31 | 13G | Kura Oncology, Inc. KURA | BIOTECHNOLOGY VALUE FUND LP | 3,408,054 4.300% | -804,292 (-19.09%) | Filing History |
| 2025-01-31 6:43 pm Purchase | 2025-01-24 | 13G | Monte Rosa Therapeutics, Inc. GLUE | BIOTECHNOLOGY VALUE FUND LP | 4,393,210 7.200% | 4,393,210 (New Position) | Filing History |
| 2025-01-29 5:12 pm Sale | 2025-01-27 | 13G | enGene Holdings Inc. Common Stock ENGN | BIOTECHNOLOGY VALUE FUND LP | 945,402 1.800% | -2,106,037 (-69.02%) | Filing History |
| 2025-01-29 5:09 pm Sale | 2024-12-31 | 13G | enGene Holdings Inc. Common Stock ENGN | BIOTECHNOLOGY VALUE FUND LP | 3,051,439 5.900% | -145,000 (-4.54%) | Filing History |
| 2025-01-28 5:19 pm Sale | 2025-01-24 | 13D | XOMA Corporation XOMA | BIOTECHNOLOGY VALUE FUND LP | 2,983,026 25.300% | -650,717 (-17.91%) | Filing History |
| 2025-01-06 6:38 pm Purchase | 2024-12-27 | 13G | RAPT Therapeutics, Inc. RAPT | BIOTECHNOLOGY VALUE FUND LP | 11,764,000 8.700% | 11,764,000 (New Position) | Filing History |
| 2024-12-23 9:25 pm Unchanged | 2024-12-19 | 13D | Inventiva S.A. IVA | BIOTECHNOLOGY VALUE FUND LP | 8,545,499 9.000% | 0 (Unchanged) | Filing History |
| 2024-12-17 5:42 pm Purchase | 2024-12-13 | 13G | Palvella Therapeutics, Inc. PVLA | BIOTECHNOLOGY VALUE FUND LP | 1,168,117 9.990% | 1,168,117 (New Position) | Filing History |
| 2024-12-04 7:49 pm Sale | 2024-12-04 | 13D | Olema Pharmaceuticals, Inc. OLMA | BIOTECHNOLOGY VALUE FUND LP | 7,557,237 9.990% | -1,578,656 (-17.28%) | Filing History |